Lewis Timothy A, de Waal Luc, Wu Xiaoyun, Youngsaye Willmen, Wengner Antje, Kopitz Charlotte, Lange Martin, Gradl Stefan, Ellermann Manuel, Lienau Philip, Schreiber Stuart L, Greulich Heidi, Meyerson Matthew
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Dana-Farber Cancer Institute, Boston, Massachusetts 01255, United States.
ACS Med Chem Lett. 2019 Oct 18;10(11):1537-1542. doi: 10.1021/acsmedchemlett.9b00360. eCollection 2019 Nov 14.
6-(4-(Diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2)-one, or , potently and selectively inhibits phosphodiesterases 3A and 3B (PDE3A and PDE3B) and kills cancer cells by inducing PDE3A/B interactions with SFLN12. The structure-activity relationship (SAR) of analogs was evaluated using a phenotypic viability assay, resulting in several compounds with suitable pharmacokinetic properties for analysis. One of these compounds, , was active in an SK-MEL-3 xenograft model of cancer.
6-(4-(二乙氨基)-3-硝基苯基)-5-甲基-4,5-二氢哒嗪-3(2)-酮,即 ,可有效且选择性地抑制磷酸二酯酶3A和3B(PDE3A和PDE3B),并通过诱导PDE3A/B与SFLN12相互作用来杀死癌细胞。使用表型活力测定法评估了 类似物的构效关系(SAR),得到了几种具有适合 分析的药代动力学性质的化合物。其中一种化合物, 在SK-MEL-3癌症异种移植模型中具有活性。